


## HPGDS inhibitor 1

<b>Cat. No.:</b>	HY-10439		
<b>CAS No.:</b>	1033836-12-2		
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>19</sub> F <sub>4</sub> N <sub>3</sub> O		
<b>Molecular Weight:</b>	381.37		
<b>Target:</b>	PGE synthase		
<b>Pathway:</b>	Immunology/Inflammation		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (131.11 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	<b>Preparing Stock Solutions</b>		10 mg	
	<b>1 mM</b>	2.6221 mL	13.1106 mL	26.2213 mL
	<b>5 mM</b>	0.5244 mL	2.6221 mL	5.2443 mL
	<b>10 mM</b>	0.2622 mL	1.3111 mL	2.6221 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution			

### BIOLOGICAL ACTIVITY

<b>Description</b>	HPGDS inhibitor 1 is a potent, selective and orally active Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC <sub>50</sub> s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 0.6 nM (HPGDS in enzyme assays) and 32 nM (HPGDS in cellular assays) <sup>[1]</sup>
<b>In Vitro</b>	HPGDS inhibitor 1 has equal potency against purified HPGDS from human, rat, dog, and sheep (IC <sub>50</sub> , 0.5-2.3 nM) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	HPGDS inhibitor 1 (compound 8; 1 mg/kg) has excellent PK characteristics with 76% bioavailability, and the T <sub>1/2</sub> is 4.1 hours in rats <sup>[1]</sup> . Rats dosed orally with 1 mg/kg and 10 mg/kg HPGDS inhibitor 1 (compound 8) are sacrificed at various times. Oral

---

administration of HPGDS inhibitor 1 blocks PGD2 production in the rat spleen; inhibition of PGD2 is inversely correlated with the plasma concentration of HPGDS inhibitor 1 in a time- and dose-dependent manner<sup>[1]</sup>.  
HPGDS inhibitor 1 (compound 8; 1 mg/mL) illustrates efficacy in an in vivo sheep model of asthma<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

---

[1]. Chris P Carron, et al. Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS). ACS Med Chem Lett. 2010 Feb 2;1(2):59-63.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA